✨ Free AI Report
RedHill Biopharma Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research RedHill Biopharma Ltd.
Company Research

RedHill Biopharma Ltd.: Business Overview, Financials & Competitive Analysis

RedHill Biopharma Ltd. scores 4/10 on the AskCyborg Cyborg Score (Mixed). De-risked pipeline with multiple near-term value catalysts (Talicia commercialization, RHB-102 Phase 2 GLP-1), but equity capital constraints and compliance challenges create near-term execution risk. RedHill shows solid pipeline progress and recent commercial activity (Talicia launch, RHB-102 advances), but faces significant operational headwinds including Nasdaq compliance violations (stockholders' equity requirement).

What is RedHill Biopharma Ltd.'s industry? RedHill Biopharma Ltd. (redhillbio.com) operates in Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases. AskCyborg classifies RedHill Biopharma Ltd. under Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases in its company registry.

RedHill Biopharma is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, oncology, and medical countermeasures...

4/ 10Mixed

Cyborg Score thesis

De-risked pipeline with multiple near-term value catalysts (Talicia commercialization, RHB-102 Phase 2 GLP-1), but equity capital...

Read the full analyst-debate transcript →
Industry Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest RedHill Biopharma Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for RedHill Biopharma Ltd.

AskCyborg analysts argue the bull and bear cases for RedHill Biopharma Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
RedHill Biopharma Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

RedHill Biopharma Ltd. Overview

Pro stress-test →

RedHill Biopharma is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, oncology, and medical countermeasures. The company is advancing a diversified pipeline addressing large market opportunities with government support for multiple programs.

Strategic Profile

Pro stress-test →

RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development, with products based on several technology platforms addressing several disease targets for risk diversification. RedHill recently began a joint U.S. commercial launch of Talicia (H. pylori treatment) with Cumberland in February 2026.

Competitive Landscape

Pro stress-test →

RedHill operates in fragmented specialty pharma markets. Primary competitors include major pharma companies in H. pylori treatment (AbbVie with legacy products), specialty infectious disease players (Cipla, others in travelers' diarrhea), and emerging biotech companies targeting GLP-1 side effects. RedHill's advantage lies in portfolio diversification and government-supported programs, though it faces competition from larger, better-capitalized companies.

Industry Context

RedHill Biopharma Ltd. operates in Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases.

Key facts

Founded: 2009 · Headquarters: Tel Aviv, Israel

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on RedHill Biopharma Ltd..

  • RHB-102 (ondansetron) shows multi-indication potential including GLP-1 GI side effects with 50% discontinuation rates at 3 months, representing up to $35B market opportunity by 2030.
  • Talicia (H. pylori) and Aemcolo (travelers' diarrhea) launched with commercial partner Cumberland, expanding U.S. market reach for core GI franchise.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026RedHill and Cumberland launched full sales and operations for Talicia (H. pylori treatment) in U.S. market
  • Jan 2026Company planning Phase 2 proof-of-concept study for RHB-102 in GLP-1 GI side effects starting early 2026 under FDA 505(b)(2) pathway
  • +1 moreTrack every material event for RedHill Biopharma Ltd. as it happens. Explore monitoring →
Get alerted when RedHill Biopharma Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

H. pylori treatmentsEstablished market with competing therapies→Travelers' diarrhea treatmentsEstablished generic market→GLP-1 side effect managementNew competitive space targeting obesity medication adverse events→

Compare RedHill Biopharma Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

RedHill Biopharma Ltd. operates in Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases research →
NEW · MCP server

Ask your AI assistant about RedHill Biopharma Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare RedHill Biopharma Ltd. and its top competitor on Cyborg Score”
“What did RedHill Biopharma Ltd. do this quarter?”
“Is RedHill Biopharma Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does RedHill Biopharma Ltd. do?+
RedHill Biopharma is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, oncology, and medical countermeasures...
What is RedHill Biopharma Ltd.'s Cyborg Score?+
RedHill Biopharma Ltd. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are RedHill Biopharma Ltd.'s main competitors?+
Named competitors include H. pylori treatments, Travelers' diarrhea treatments, GLP-1 side effect management. The full competitive landscape is in the AskCyborg report.
How can I get the full RedHill Biopharma Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the RedHill Biopharma Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track RedHill Biopharma Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.